Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation

Bone Marrow Transplantation volume 52, pages 769–771 (2017)Cite this article

Subjects

The use of T-cell replete grafts from HLA-haploidentical (haplo) donors, with post-transplant cyclophosphamide (PTCy) for acute GvHD (aGvHD) prophylaxis, is efficacious in patients who do not have a matched sibling or timely access to a matched unrelated donor.1, 2 Early studies investigating haplo hematopoietic cell transplantation (HCT) with PTCy used bone marrow grafts to help mitigate the risk of GvHD; however, disease relapse remains the major cause of transplant failure.2, 3 At Washington University School of Medicine, we have almost exclusively used G-CSF mobilized (PBSC) grafts for haplo-HCT. The goal of this study is to present our experience utilizing this haplo-HCT platform to treat various hematologic malignancies as a follow-up to previously published preliminary data.4

We retrospectively evaluated 102 adult patients who underwent haplo-HCT for various hematologic malignancies at Washington University Medical Center from July 2009 through May 2015. This study was approved by the Institutional Review Board of Washington University School of Medicine in Saint Louis. Patient outcomes were monitored by retrospective chart review through the end of June 2016 with a median follow-up of 19.5 months (range 6.8–63.1 months) for survivors. This was a high-risk patient population with 56 patients having active disease at the time of their transplant, 42 had high risk cytogenetics, 24 had a previous allo-HCT and only 18 patients were transplanted in their first CR. Patient, disease and transplant characteristics are listed in Table 1.

Table 1 Patient and transplant characteristics
Full size table

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  Google Scholar 

  2. McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolanos-Meade J, Rosner GL et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015; 125: 3024–3031.

    Article  CAS  Google Scholar 

  3. Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010; 115: 3224–3230.

    Article  CAS  Google Scholar 

  4. Bhamidipati PK, DiPersio JF, Stokerl-Goldstein K, Rashidi A, Gao F, Uy GL et al. Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. Bone Marrow Transplant 2014; 49: 1124–1126.

    Article  CAS  Google Scholar 

  5. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013; 31: 1310–1316.

    Article  CAS  Google Scholar 

  6. Gladstone DE, Zachary AA, Fuchs EJ, Luznik L, Kasamon YL, King KE et al. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant 2013; 19: 647–652.

    Article  CAS  Google Scholar 

  7. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012; 119: 296–307.

    Article  CAS  Google Scholar 

  8. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074–5087.

    Article  Google Scholar 

  9. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012; 18: 1859–1866.

    Article  Google Scholar 

  10. Sugita J, Kawashima N, Fujisaki T, Kakihana K, Ota S, Matsuo K et al. HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant 2015; 21: 1646–1652.

    Article  Google Scholar 

  11. Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014; 20: 890–895.

    Article  Google Scholar 

  12. Castagna L, Crocchiolo R, Furst S, Bramanti S, El Cheikh J, Sarina B et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014; 20: 724–729.

    Article  Google Scholar 

  13. Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ et al. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep 2011; 3 (Suppl 2): e15.

    PubMed  PubMed Central  Google Scholar 

  14. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant 2014; 20: 1975–1981.

    Article  Google Scholar 

  15. Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol 2016; 34: 329–336.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. E Huselton and M Slade: These authors contributed equally to this work.

Authors and Affiliations

  1. Bone Marrow Transplant and Leukemia Program, Washington University School of Medicine, Saint Louis, MO, USA

    E Huselton, M Slade, J F DiPersio, P Westervelt, R Vij, G L Uy, T A Fehniger, C N Abboud, M A Schroeder & R Romee

  2. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, Saint Louis, MO, USA

    F Gao

Authors
  1. E Huselton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Slade
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J F DiPersio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Westervelt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Vij
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G L Uy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T A Fehniger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C N Abboud
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M A Schroeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R Romee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Romee.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huselton, E., Slade, M., DiPersio, J. et al. Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 52, 769–771 (2017). https://doi.org/10.1038/bmt.2016.354

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.354

This article is cited by

Search

Advanced search

Quick links